Recently, the innovative drug sector has rebounded, and clinical progress and overseas cooperation have continued to receive market attention. According to the interim report data, the pharmaceutical industry's profit growth rate is faster than revenue growth. The commercialization volume of innovative pharmaceutical companies and the recovery in CXO orders have become an important support for improving profits. Analysts believe that innovative drugs in China are shifting from being driven by research and development to commercialization, and overseas clinical promotion and product approval are expected to open up room for subsequent earnings; the recovery in domestic and foreign R&D demand will also be transmitted to the CXO industry chain. In the future, we can focus on innovative pharmaceutical companies with product release, differentiated R&D and continuous overseas marketing capabilities, as well as CXO leaders with good performance and order performance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.